<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003462</url>
  </required_header>
  <id_info>
    <org_study_id>0672</org_study_id>
    <secondary_id>DUMC-0672-03-3R5</secondary_id>
    <secondary_id>DUMC-000672-02-3R4</secondary_id>
    <secondary_id>DUMC-000672-00-3R2</secondary_id>
    <secondary_id>DUMC-000672-01-3R3</secondary_id>
    <secondary_id>DUMC-0631-99-4RI</secondary_id>
    <secondary_id>DUMC-625-98-4</secondary_id>
    <secondary_id>DUMC-98045</secondary_id>
    <secondary_id>DUMC-FDR001519</secondary_id>
    <secondary_id>NCI-G98-1463</secondary_id>
    <secondary_id>CDR0000066494</secondary_id>
    <nct_id>NCT00003462</nct_id>
  </id_info>
  <brief_title>Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors</brief_title>
  <official_title>Phase I Study of Intrathecal Spartaject-Busulfan in Patients With Neoplastic Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Giving drugs into the thin space between the lining of the spinal&#xD;
      cord and brain may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of intrathecal busulfan in treating&#xD;
      patients with recurrent, refractory, or metastatic leptomeningeal tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of intrathecal busulfan by a limited escalation&#xD;
           dosage schedule in patients with recurrent or refractory leptomeningeal tumors.&#xD;
&#xD;
        -  Determine the cerebrospinal fluid and serum pharmacokinetics of busulfan administered&#xD;
           via intralumbar or intraventricular routes in these patients.&#xD;
&#xD;
      OUTLINE: This is dose-escalation study.&#xD;
&#xD;
      Patients receive intrathecal busulfan via intralumbar or intraventricular routes twice a week&#xD;
      for 2 weeks (4 treatments). Any patient with objective or significant clinical response may&#xD;
      continue treatment by receiving the same dose once a week for 2 consecutive weeks, once a&#xD;
      week every other week for 3 weeks (2 treatments), and then once a month thereafter until&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of intrathecal busulfan until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 12 weeks for 1 year or until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 5-20 patients will be accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">February 2001</completion_date>
  <primary_completion_date type="Actual">February 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed neoplasm that is metastatic in the cerebrospinal fluid or&#xD;
             leptomeningeal/subarachnoid space&#xD;
&#xD;
               -  Cytologic diagnosis of malignancy in the cerebrospinal fluid or neuroimaging&#xD;
                  evidence of leptomeningeal tumor by MRI&#xD;
&#xD;
          -  Must have a recurrent or refractory leptomeningeal tumor&#xD;
&#xD;
               -  Leptomeningeal tumors of leukemia, lymphoma, and all germ cell tumors must have&#xD;
                  also failed initial treatment or be recurrent&#xD;
&#xD;
          -  No evidence of obstructive hydrocephalus or complete block of the spinal cerebrospinal&#xD;
             fluid pathways on prestudy technetium Tc 99m albumin or indium In 111 DTPA flow study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.5 mg/dL&#xD;
&#xD;
          -  SGOT or SGPT less than 1.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN less than 30 mg/dL&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
          -  Calcium within normal limits&#xD;
&#xD;
        Neurological:&#xD;
&#xD;
          -  Neurological examination stable&#xD;
&#xD;
          -  No rapidly progressing or deteriorating neurological deficits&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infectious process&#xD;
&#xD;
          -  Magnesium, phosphorus, potassium, chloride, and bicarbonate normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas or mitomycin&#xD;
&#xD;
          -  At least 4 weeks since any other prior chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior intrathecal chemotherapy&#xD;
&#xD;
          -  No other concurrent intrathecal chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  For patients on corticosteroids:&#xD;
&#xD;
               -  Must be on a stable dose of corticosteroids for at least 1 week&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy to the CNS&#xD;
&#xD;
          -  At least 4 weeks since any other prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy to the CNS&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent medication that may interfere with study results (e.g.,&#xD;
             immunosuppressive agents other than corticosteroids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry S. Friedman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leptomeningeal metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

